EUVIMEDEUVIMED entdecken
Crossref

Noninvasive therapy of brain cancer using a unique systemic delivery methodology with a cancer terminator virus

Praveen Bhoopathi, Padmanabhan Mannangatti, Anjan K Pradhan, Amit Kumar, Santanu Maji, Frederick F Lang, Alexander L Klibanov, Esha Madan, Webster K Cavenee, Timothy Keoprasert, Dong Sun, Rolf Bjerkvig und 5 weitere

Journal of Cellular Physiology · 2024

DOI: 10.1002/jcp.31302 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular Physiology, 2024. Verfasst von Praveen Bhoopathi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Blood-Brain Barrier, Adenoviridae. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: NCI NIH HHS, Sherman Fairchild Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary, glioblastoma, and secondary brain tumors, from metastases outside the brain, are among the most aggressive and therapeutically resistant cancers. A physiological barrier protecting the brain, the blood–brain barrier (BBB), functions as a deterrent to effective therapies. To enhance cancer therapy, we developed a cancer terminator virus ( CTV ), a unique tropism‐modified adenovirus consisting of serotype 3 fiber knob on an otherwise Ad5 capsid that replicates in a cancer‐selective manner and simultaneously produces a potent therapeutic cytokine, melanoma differentiation‐associated gene‐7/interleukin‐24 (MDA‐7/IL‐24). A limitation of the CTV and most other viruses, including adenoviruses, is an inability to deliver systemically to treat brain tumors because of the BBB, nonspecific virus trapping, and immune clearance. These obstacles to effective viral therapy of brain cancer have now been overcome using focused ultrasound with a dual microbubble treatment, the focused ultrasound‐double microbubble (FUS‐DMB) approach. Proof‐of‐principle is now provided indicating that the BBB can be safely and transiently opened, and the CTV can then be administered in a second set of complement‐treated microbubbles and released in the brain using focused ultrasound. Moreover, the FUS‐DMB can be used to deliver the CTV multiple times in animals with glioblastoma growing in their brain thereby resulting in a further enhancement in survival. This strategy permits efficient therapy of primary and secondary brain tumors enhancing animal survival without promoting harmful toxic or behavioral side effects. Additionally, when combined with a standard of care therapy, Temozolomide, a further increase in survival is achieved. The FUS‐DMB approach with the CTV highlights a noninvasive strategy to treat brain cancers without surgery. This innovative delivery scheme combined with the therapeutic efficacy of the CTV provides a novel potential translational therapeutic approach for brain cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsBlood-Brain BarrierAdenoviridaeAnimalsHumansInterleukinsCell Line, TumorMicrobubblesMiceGlioblastomaXenograft Model Antitumor AssaysOncolytic VirotherapyGenetic VectorsTemozolomideMice, NudeInterleukin-24

Stichwörter der Autor:innen

FUS‐DMB strategyGBMcancer terminator virusmetastatic brain tumortemozolomide

Substanzen

InterleukinsTemozolomideInterleukin-24

Autor:innen und Institutionen

  • Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
  • VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
  • Department of Neurosurgery, MD Anderson Cancer Center, Houston, Texas, USA.
  • Biomedical Engineering, Radiology and Medical Imaging, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.
  • Department of Surgery, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA.
  • Ludwig Institute for Cancer Research, University of San Diego, La Jolla, California, USA.

ORCID-Profile: Frits Thorsen

Förderung

  • NCI NIH HHS
  • Sherman Fairchild Foundation

Zitieren

APA

Bhoopathi, P., Mannangatti, P., Pradhan, A. K., Kumar, A., Maji, S., Lang, F. F., Klibanov, A. L., Madan, E., Cavenee, W. K., Keoprasert, T., Sun, D., Bjerkvig, R., Thorsen, F., Gogna, R., Das, S. K., Emdad, L., & Fisher, P. B. (2024). Noninvasive therapy of brain cancer using a unique systemic delivery methodology with a cancer terminator virus. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.31302

Vancouver

Bhoopathi P, Mannangatti P, Pradhan AK, Kumar A, Maji S, Lang FF, et al. Noninvasive therapy of brain cancer using a unique systemic delivery methodology with a cancer terminator virus. Journal of Cellular Physiology. 2024. doi:10.1002/jcp.31302

BibTeX
@article{Bhoopathi2024,
  author = {Bhoopathi, Praveen and Mannangatti, Padmanabhan and Pradhan, Anjan K and Kumar, Amit and Maji, Santanu and Lang, Frederick F and Klibanov, Alexander L and Madan, Esha and Cavenee, Webster K and Keoprasert, Timothy and Sun, Dong and Bjerkvig, Rolf and Thorsen, Frits and Gogna, Rajan and Das, Swadesh K and Emdad, Luni and Fisher, Paul B},
  title = {Noninvasive therapy of brain cancer using a unique systemic delivery methodology with a cancer terminator virus},
  journal = {Journal of Cellular Physiology},
  year = {2024},
  doi = {10.1002/jcp.31302}
}
Kostenlos starten →